Biological Principles and Perspectives
  • Hak Choy
  • Robert M. MacRae
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The medical uses of ionizing radiation have expanded dramatically since Wilhelm Roentgen first discovered it at the end of the last century. In particular, it has proven to be an effective agent in the ongoing battle against cancer. It is presumed that the essential target for radiation is cellular DNA where it acts through the formation of free radicals to directly or indirectly cause double-stranded breaks. It is these double-stranded breaks in the DNA that are felt to be the lethal lesion that malignant cells sustain from therapeutic radiation.


Epidermal Growth Factor Receptor Radiat Oncol Biol Phys Tumor Hypoxia Prophylactic Cranial Irradiation Combine Modality Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963; 105: 574–578.PubMedCrossRefGoogle Scholar
  2. 2.
    Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21 (1): 109–122.PubMedCrossRefGoogle Scholar
  3. 3.
    Trott KR, Kummermehr J. What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother Oncol 1985; 3 (1): 1–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Trott KR. The mechanisms of acceleration of repopulation in squamous epithelia during daily irradiation. Acta Oncol 1999; 38 (2): 153–157.PubMedCrossRefGoogle Scholar
  5. 5.
    Fowler JF. Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991; 22 (3): 156–158.PubMedCrossRefGoogle Scholar
  6. 6.
    Dorr W, Kummermehr J. Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother Oncol 1990; 17 (3): 249–259.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu K, Kasper M, Bierhaus A, et al. Connexin 43 expression in normal and irradiated mouse skin. Radiat Res 1997; 147 (4): 437–441.PubMedCrossRefGoogle Scholar
  8. 8.
    Bristow RG, Hill RP. Molecular and cellular basis of radiotherapy. In Tannock IF, Hill RP, eds. The Basic Science of Oncology. Third edition. Montreal: McGraw-Hill; 1998. pp. 295–321.Google Scholar
  9. 9.
    Hall EJ. Radiobiology for the Radiologist. Fourth Edition. Philadelphia: JB Lippincott; 1994. pp 133–152.Google Scholar
  10. 10.
    Rosen EM, Fan S, Goldberg ID, et al. Biological basis of radiation sensitivity. Part 1: Factors governing radiation tolerance. Oncology (Hunting)) 2000; 14 (4): 543–550.Google Scholar
  11. 11.
    Saunders MI. Head and neck cancer: altered fractionation schedules. Oncologist 1999; 4 (1): 11–16.PubMedGoogle Scholar
  12. 12.
    Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin lvels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86 (8): 1528–1536.PubMedCrossRefGoogle Scholar
  13. 13.
    Kapp DS, Fischer D, Gutierrez E, et al. Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariate analysis of the effect of age, stage, histology and blood counts on survival. Int J Rad Onc Biol Phys 1983; 9: 44–53.Google Scholar
  14. 14.
    Warde P, O’Sullivan B, Bristow R, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Rad Onc Biol Phys 1998; 41 (2): 347–353.CrossRefGoogle Scholar
  15. 15.
    Lee WR, Berkley B, Marcial V, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85–27. Int J Rad Onc Biol Phys 1998; 42 (5): 1069–1075.CrossRefGoogle Scholar
  16. 16.
    Pollack A, Zagars GK, Dinney CP, et al. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 1994; 74 (10): 2819–2827.PubMedCrossRefGoogle Scholar
  17. 17.
    Brizel DM, Scully SP, Harrelson JM et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996; 56 (23): 5347–5350.PubMedGoogle Scholar
  18. 18.
    Becker A, Hansgen G, Bloching M, et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Ina J Rad Onc Biol Phys 1998; 42 (1): 35–41.CrossRefGoogle Scholar
  19. 19.
    Brizel DM, Rosner GL, Prosnitz LR, et al. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 1995 Jul 15; 32 (4): 1121–1125.CrossRefGoogle Scholar
  20. 20.
    Hockel M, Schlenger K, Hockel S, et al. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998 Aug 21; 79 (4): 365–369.CrossRefGoogle Scholar
  21. 21.
    Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Nail Cancer Inst 2001 Feb 21; 93 (4): 266–276.CrossRefGoogle Scholar
  22. 22.
    Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. Free Radic Biol Med 1995; 18(6):1033–1077.PubMedCrossRefGoogle Scholar
  23. 23.
    Sutherland RM. Tumor hypoxia and gene expression-implications for malignant progression and therapy. Acta Oncol 1998; 37 (6): 567–574.PubMedCrossRefGoogle Scholar
  24. 24.
    Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36 (13 Spec No): 1649–1660.PubMedCrossRefGoogle Scholar
  25. 25.
    De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology, 5th edition. Lippincott-Raven. 1997. pp. 858–910.Google Scholar
  26. 26.
    Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66 (3): 439–449.PubMedGoogle Scholar
  27. 27.
    Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979 Jan; 5 (1): 85–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Laver JH, Barredo JC, Amylon M, et al. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. Leukemia 2000; 14 (3): 369–373.PubMedCrossRefGoogle Scholar
  29. 29.
    Dubey AK, Recht A, Come S, et al. Why and how to combine chemotherapy and radiation therapy in breast cancer patients. Recent Results Cancer Res 1998; 152: 247–254.PubMedCrossRefGoogle Scholar
  30. 30.
    Wolff JA, Newton WA Jr, Krivit W, et al. Single versus multiple dose dactinomycin therapy of Wilms’s tumor. A controlled co-operative study conducted by the Children’ s Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med 1968; 279 (6): 290–294.PubMedCrossRefGoogle Scholar
  31. 31.
    Lindegaard J C, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000; 57 (2): 113–118.Google Scholar
  32. 32.
    Vokes EE, Haraf DJ, Drinkard LC, et al. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol 1995; 35 (4): 304–312.PubMedCrossRefGoogle Scholar
  33. 33.
    Danilenko DM. Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999; 27 (1): 64–71.PubMedCrossRefGoogle Scholar
  34. 34.
    Phillips TL. Chemical modification of radiation effects. Cancer 1977 Feb; 39 (2 Suppl): 987–998.PubMedCrossRefGoogle Scholar
  35. 35.
    Herscher LL, Cook JA, Pacelli R, et al. Principles of chemoradiation: theoretical and practical considerations. Oncology (Huntingt) 1999 Oct; 13(10 Suppl 5):11–22.Google Scholar
  36. 36.
    Franken NA, Van Bree CV, Kipp JB, et al. Modification of potentially lethal damage in irradiated Chinese hamster V79 cells after incorporation of halogenated pyrimidines. Int J Radiat Biol 1997; 72 (1): 101–109.PubMedCrossRefGoogle Scholar
  37. 37.
    Kinsella TJ, Dobson PP, Mitchell JB, et al. Enhancement of X ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987; 13 (5): 733–739.PubMedCrossRefGoogle Scholar
  38. 38.
    Dolling JA, Boreham DR, Brown DL, et al. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int J Radiat Biol 1998; 74 (1): 61–69.PubMedCrossRefGoogle Scholar
  39. 39.
    Amorino GP, Freeman ML, Carbone DP, et al. Radiopotentiation by the oral platinum agent, JM21 6: role of repair inhibition. Int J Radiat Oncol Biol Phys 1999; 44 (2): 399–405.PubMedCrossRefGoogle Scholar
  40. 40.
    Milas L, Midas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 12–26.PubMedGoogle Scholar
  41. 41.
    Milas L, Hunter NR, Mason KA et al. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995; 55 (16): 3564–3568.PubMedGoogle Scholar
  42. 42.
    Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999; 44 (5): 1125–1135.PubMedCrossRefGoogle Scholar
  43. 43.
    Lawrence TS, Eisbruch A, McGinn CJ, et al. Radiosensitization by gemcitabine. Oncology (Huntingt) 1999; 13 (10 Suppl 5): 55–60.Google Scholar
  44. 44.
    Phillips T. Biochemical Modifiers: Drug-Radiation Interactions. In Mauch PM, Loeffler JS, eds. Radiation Oncology: Technology and Biology. Philadelphia: WB Saunders Company; 1994. pp. 113–152.Google Scholar
  45. 45.
    Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974; 17 (3): 354–356.PubMedCrossRefGoogle Scholar
  46. 46.
    Cummings BJ, Keane TJ, O’ Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Rad Onc Biol Phys 1991; 21(5):115–125.Google Scholar
  47. 47.
    Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040–2049.PubMedGoogle Scholar
  48. 48.
    Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoidcarcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14: 2527–2539.PubMedGoogle Scholar
  49. 49.
    UKCCCR: Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996; 348: 1049–1054.Google Scholar
  50. 50.
    Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17 (5): 1339–1348.PubMedGoogle Scholar
  51. 51.
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340 (15): 1144–1153.PubMedCrossRefGoogle Scholar
  52. 52.
    Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340 (15): 1154–1161.PubMedCrossRefGoogle Scholar
  53. 53.
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340 (15): 1137–1143.PubMedCrossRefGoogle Scholar
  54. 54.
    Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18 (8): 1606–1613.PubMedGoogle Scholar
  55. 55.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992 Dec 3; 327 (23): 1618–1624.CrossRefGoogle Scholar
  56. 56.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10 (6): 890–895.PubMedGoogle Scholar
  57. 57.
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340 (4): 265–271.PubMedCrossRefGoogle Scholar
  58. 58.
    Kotalik J, Yu E, Markman BR, et al. Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 50 (2): 309–316.PubMedCrossRefGoogle Scholar
  59. 59.
    Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341 (7): 476–484.PubMedCrossRefGoogle Scholar
  60. 60.
    Neville HL, Ritchey ML. Wilms’ tumor. Overview of National Wilms’ Tumor Study Group results. Urol Clin North Am 2000; 27 (3): 435–442.PubMedCrossRefGoogle Scholar
  61. 61.
    Meyn RE. Apoptosis and response to radiation: implications for radiation therapy. Oncology (Huntingt) 1997; 11 (3): 349–356.Google Scholar
  62. 62.
    Li L, Story M, Legerski RJ. Cellular responses to ionizing radiation damage. IntJRadiat Oncol Biol Phys 2001; 49 (4): 1157–1162.CrossRefGoogle Scholar
  63. 63.
    Boubnov NV, Hall KT, Wills Z, et al. Complementation of the ionizing radiation sensitivity, DNA end binding, and V(D)J recombination defects of double-strand break repair mutants by the p86 Ku autoantigen. Proc Natl Acad Sci USA 1995; 92 (3): 890–894.PubMedCrossRefGoogle Scholar
  64. 64.
    Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA double stranded breaks by homologous recombination. Nature 1999; 401: 397–399.PubMedGoogle Scholar
  65. 65.
    Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6 (4): 157–162.PubMedCrossRefGoogle Scholar
  66. 66.
    Roth JA, Grammer SF, Swisher SG, et al. Gene replacement strategies for treating non-small cell lung cancer. Semin Radiat Oncol 2000; 10 (4): 333–342.PubMedCrossRefGoogle Scholar
  67. 67.
    Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996; 40 (3): 197–223.PubMedCrossRefGoogle Scholar
  68. 68.
    Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced nonsmall-cell lung cancer. J Natl Cancer Inst 1999; 91 (9): 763–771.PubMedCrossRefGoogle Scholar
  69. 69.
    Schuler M, Rochlitz C, Horowitz JA, et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 1998; 9 (14): 2075–2082.PubMedCrossRefGoogle Scholar
  70. 70.
    Schuler M, Herrmann R, De Greve JL, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19 (6): 1750–1758.PubMedGoogle Scholar
  71. 71.
    Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000; 6 (6): 2513–2520.PubMedGoogle Scholar
  72. 72.
    Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 Suppl 1: 15–23.Google Scholar
  73. 73.
    Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18 (21 Suppl): 54S - 9S.PubMedGoogle Scholar
  74. 74.
    Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol 2000; 27 (6 Suppl 11): 15–20.PubMedGoogle Scholar
  75. 75.
    Micas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6 (2): 701–708.Google Scholar
  76. 76.
    Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000; 48 (5): 1519–1528.PubMedCrossRefGoogle Scholar
  77. 77.
    Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89 (2): 139–147.PubMedCrossRefGoogle Scholar
  78. 78.
    Katoh O, Tauchi H, Kawaishi K, et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55 (23): 5687–5692.PubMedGoogle Scholar
  79. 79.
    Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61 (6): 2413–2419.PubMedGoogle Scholar
  80. 80.
    Schenk PW, Snaar-Jagalska BE. Signal perception and transduction: the role of protein kinases. Biochim Biophys Acta 1999; 1449 (1): 1–24.PubMedCrossRefGoogle Scholar
  81. 81.
    O’Brian C, Vogel VG, Singletary SE, et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49 (12): 3215–3217.PubMedGoogle Scholar
  82. 82.
    Benzil DL, Finkelstein SD, Epstein MH, et al. Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression. Cancer Res 1992; 52 (10): 2951–2956.PubMedGoogle Scholar
  83. 83.
    Kopp R, Noelke B, Sauter G, et al. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas. Cancer Res 1991; 51 (1): 205–210.PubMedGoogle Scholar
  84. 84.
    Fabbro D, Ruetz S, Bodis S, et al. PKC412—a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15 (1): 17–28.PubMedGoogle Scholar
  85. 85.
    Zaugg K, Rocha S, Resch H, et al. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001; 61 (2): 732–738.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Hak Choy
  • Robert M. MacRae

There are no affiliations available

Personalised recommendations